These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 37425702)

  • 1. Two Classes of DNA Gyrase Inhibitors Elicit Distinct Evolutionary Trajectories Toward Resistance in Gram-Negative Pathogens.
    Leyn SA; Kent JE; Zlamal JE; Elane ML; Vercruysse M; Osterman AL
    bioRxiv; 2023 Sep; ():. PubMed ID: 37425702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Shared and Unique Evolutionary Trajectories to Ciprofloxacin Resistance in Gram-Negative Bacterial Pathogens.
    Zlamal JE; Leyn SA; Iyer M; Elane ML; Wong NA; Wamsley JW; Vercruysse M; Garcia-Alcalde F; Osterman AL
    mBio; 2021 Jun; 12(3):e0098721. PubMed ID: 34154405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experimental evolution in morbidostat reveals converging genomic trajectories on the path to triclosan resistance.
    Leyn SA; Zlamal JE; Kurnasov OV; Li X; Elane M; Myjak L; Godzik M; de Crecy A; Garcia-Alcalde F; Ebeling M; Osterman AL
    Microb Genom; 2021 May; 7(5):. PubMed ID: 33945454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Investigation of fluoroquinolone resistance mechanisms in clinical Acinetobacter baumannii isolates].
    Güler G; Eraç B
    Mikrobiyol Bul; 2016 Apr; 50(2):278-86. PubMed ID: 27175500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Bacterial Topoisomerase Inhibitors with Potent Broad-Spectrum Activity against Drug-Resistant Bacteria.
    Charrier C; Salisbury AM; Savage VJ; Duffy T; Moyo E; Chaffer-Malam N; Ooi N; Newman R; Cheung J; Metzger R; McGarry D; Pichowicz M; Sigerson R; Cooper IR; Nelson G; Butler HS; Craighead M; Ratcliffe AJ; Best SA; Stokes NR
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Properties of AdeABC and AdeIJK efflux systems of Acinetobacter baumannii compared with those of the AcrAB-TolC system of Escherichia coli.
    Sugawara E; Nikaido H
    Antimicrob Agents Chemother; 2014 Dec; 58(12):7250-7. PubMed ID: 25246403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Landscape of Phenotypic and Transcriptional Responses to Ciprofloxacin in Acinetobacter baumannii: Acquired Resistance Alleles Modulate Drug-Induced SOS Response and Prophage Replication.
    Geisinger E; Vargas-Cuebas G; Mortman NJ; Syal S; Dai Y; Wainwright EL; Lazinski D; Wood S; Zhu Z; Anthony J; van Opijnen T; Isberg RR
    mBio; 2019 Jun; 10(3):. PubMed ID: 31186328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limited Multidrug Resistance Efflux Pump Overexpression among Multidrug-Resistant Escherichia coli Strains of ST131.
    Camp J; Schuster S; Vavra M; Schweigger T; Rossen JWA; Reuter S; Kern WV
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33468485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upregulation of AcrEF in Quinolone Resistance Development in Escherichia coli When AcrAB-TolC Function Is Impaired.
    Zhang CZ; Chang MX; Yang L; Liu YY; Chen PX; Jiang HX
    Microb Drug Resist; 2018; 24(1):18-23. PubMed ID: 28520511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotypic and molecular characterization of Acinetobacter baumannii clinical isolates from nosocomial outbreaks in Los Angeles County, California.
    Valentine SC; Contreras D; Tan S; Real LJ; Chu S; Xu HH
    J Clin Microbiol; 2008 Aug; 46(8):2499-507. PubMed ID: 18524965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Fluoroquinolones and Gram-negative bacteria: antimicrobial activity and mechanisms of resistance].
    Luzzaro F
    Infez Med; 2008 Apr; 16 Suppl2():5-11. PubMed ID: 18843219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolutionary analysis of gyrA gene from Neisseria meningitidis bacterial strains of clonal complex 4821 collected in China between 1978 and 2016.
    Zhao P; Xu L; Zhang A; Zhu B; Shao Z
    BMC Microbiol; 2020 Mar; 20(1):71. PubMed ID: 32228482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug Efflux Pump Inhibitors: A Promising Approach to Counter Multidrug Resistance in Gram-Negative Pathogens by Targeting AcrB Protein from AcrAB-TolC Multidrug Efflux Pump from
    Alenazy R
    Biology (Basel); 2022 Sep; 11(9):. PubMed ID: 36138807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insertion sequence disruption of adeR and ciprofloxacin resistance caused by efflux pumps and gyrA and parC mutations in Acinetobacter baumannii.
    Lopes BS; Amyes SG
    Int J Antimicrob Agents; 2013 Feb; 41(2):117-21. PubMed ID: 23217848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ciprofloxacin and the fluoroquinolones. New concepts on the mechanism of action and resistance.
    Fisher LM; Lawrence JM; Josty IC; Hopewell R; Margerrison EE; Cullen ME
    Am J Med; 1989 Nov; 87(5A):2S-8S. PubMed ID: 2574005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibacterial small molecules targeting the conserved TOPRIM domain of DNA gyrase.
    Walker SS; Labroli M; Painter RE; Wiltsie J; Sherborne B; Murgolo N; Sher X; Mann P; Zuck P; Garlisi CG; Su J; Kargman S; Xiao L; Scapin G; Salowe S; Devito K; Sheth P; Buist N; Tan CM; Black TA; Roemer T
    PLoS One; 2017; 12(7):e0180965. PubMed ID: 28700746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibacterial activity of novel dual bacterial DNA type II topoisomerase inhibitors.
    D'Atanasio N; Capezzone de Joannon A; Di Sante L; Mangano G; Ombrato R; Vitiello M; Bartella C; Magarò G; Prati F; Milanese C; Vignaroli C; Di Giorgio FP; Tongiani S
    PLoS One; 2020; 15(2):e0228509. PubMed ID: 32074119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution toward high-level fluoroquinolone resistance in Francisella species.
    Sutera V; Levert M; Burmeister WP; Schneider D; Maurin M
    J Antimicrob Chemother; 2014 Jan; 69(1):101-10. PubMed ID: 23963236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluoroquinolone resistance mechanisms in an Escherichia coli isolate, HUE1, without quinolone resistance-determining region mutations.
    Sato T; Yokota S; Uchida I; Okubo T; Usui M; Kusumoto M; Akiba M; Fujii N; Tamura Y
    Front Microbiol; 2013; 4():125. PubMed ID: 23745120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of fluoroquinolone resistance in Escherichia coli isolates from food-producing animals.
    Karczmarczyk M; Martins M; Quinn T; Leonard N; Fanning S
    Appl Environ Microbiol; 2011 Oct; 77(20):7113-20. PubMed ID: 21856834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.